Suppr超能文献

拉沙热疫苗候选物的研究综述。

A review of Lassa fever vaccine candidates.

机构信息

R & D Blueprint for the Prevention of Epidemics, Room 3170, World Health Organization Headquarters, 20, Avenue Appia, Geneva 1211, Switzerland.

Coalition for Epidemic Preparedness Innovations, Marcus Thranes Gate 2, 0473 Oslo, Norway.

出版信息

Curr Opin Virol. 2019 Aug;37:105-111. doi: 10.1016/j.coviro.2019.07.006. Epub 2019 Aug 28.

Abstract

Lassa fever is a zoonotic disease caused by the Lassa virus, a rodent-borne arenavirus endemic to West Africa. Recent steady increase in reported cases of the disease in Nigeria, where 123 deaths occurred in 546 confirmed cases in 2019 has further underlined the need to accelerate the development of vaccines for preventing the disease. Intensified research and development of Lassa fever medical countermeasures have yielded some vaccine candidates with preclinical scientific plausibility using predominantly novel technology. The more advanced candidates are based on recombinant measles, Vesicular Stomatitis Virus or Mopiea and Lassa virus reassortants expressing Lassa virus antigens, and the deoxyribonucleic acid platform. However, the Lassa fever portfolio still lags behind other neglected tropical diseases', and further investments are needed for continued development and additional research, such as the safety and efficacy of these vaccine candidates in special populations.

摘要

拉沙热是一种由拉沙病毒引起的人畜共患病,拉沙病毒是一种在西非流行的啮齿动物传播的沙粒病毒。最近,尼日利亚报告的病例数量稳步增加,在 2019 年,123 人死亡,546 例确诊病例,这进一步强调了需要加快开发预防这种疾病的疫苗。拉沙热医疗对策的强化研究和开发已经产生了一些具有临床前科学合理性的疫苗候选物,主要使用了新型技术。更先进的候选物基于重组麻疹、水疱性口炎病毒或 Mopiea 和拉沙病毒重配体,表达拉沙病毒抗原,以及脱氧核糖核酸平台。然而,拉沙热疫苗组合仍落后于其他被忽视的热带病,需要进一步投资,以继续开发和进行更多的研究,如这些疫苗候选物在特殊人群中的安全性和有效性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验